Medicis to Present at Thomas Weisel Partners Growth Forum Conference

SCOTTSDALE, Ariz.--June 22, 2001--Medicis Pharmaceutical Corporation (NYSE:MRX) today announced that a live webcast of its presentation scheduled for Tuesday, June 26, 2001, at 3 p.m. Pacific Time (6 p.m. Eastern Time), may be accessed via the Internet.

Medicis is scheduled to present at the Thomas Weisel Partners Growth Forum 3.0 at the Bacara Resort in Santa Barbara, California.

The webcast will be available via a link on the Medicis corporate web site at http://www.medicis.com/ir/index.html. This link will allow any visitor to the web site to access the Medicis presentation. An archive of the webcast will be available on the Medicis corporate web site at the same URL address for two business days following the live presentation.

Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology, including acne, fungal infections, psoriasis, eczema, rosacea, skin and skin-structure infections, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN(R) (minocycline HCl), TRIAZ(R) (benzoyl peroxide), LUSTRA(R) (hydroquinone), LUSTRA-AF(R) (hydroquinone) with sunscreen, LOPROX(R) (ciclopirox), PLEXION(TM) (sodium sulfacetamide/sulfur), PLEXION-TS(TM) (sodium sulfacetamide/sulfur), OMNICEF(R) (cefdinir), OVIDE(R) (malathion), LIDEX(R) (fluocinonide), SYNALAR(R) (fluocinolone acetonide), TOPICORT(R) (desoximetasone) and A/T/S(R) (erythromycin); the over-the-counter brand ESOTERICA(R); and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder.

Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions and other risks described from time to time in the Company's SEC filings. These forward-looking statements represent the judgment of the Company, as of the date of this release, and Medicis disclaims any intent or obligation to update these forward-looking statements.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company. OMNICEF(R)is a registered trademark of Abbott Laboratories, Inc.

Contacts:
Medicis Pharmaceutical Corporation, Scottsdale
Libby Ivy, 602/808-3854
www.medicis.com